Samuel Stursberg

Bellevue Asset Management AG (Bellevue AM) is the wholly-owned asset management subsidiary of Bellevue Group AG (SWX: BBN), an independent Swiss financial group. The firm is headquartered in Küsnacht, Switzerland and has additional offices in Germany, Austria and Luxembourg. Founded in 1993, Bellevue AM provides a diverse spectrum of top-tier investment solutions with a focus on global healthcare sector for private and institutional clients. They offer their flagship investment vehicle, the listed investment company BB Biotech AG.

Adamant Biomedical Investments AG (Adamant) is the subsidiary of Bellevue Group AG (SW: BBN) in Switzerland. The firm was established in 2000 as a joint venture between Swiss Life Asset Management and three partners, formerly with the Bellevue Group (which comprises BB Biotech and BB Medtech). The firm's name derives from the Greek word for 'uncut diamond' and refers to their philosophy of uncovering hidden value. Located in Zurich, Adamant is a biomedical sector specialist. The firm manages sector-specific portfolios domiciled in Luxembourg. Their clients are institutions.